Emergent BioSolutions (EBS) Common Equity (2010 - 2026)

Emergent BioSolutions' Common Equity history runs 17 years deep, the most recent figure standing at $523.1 million for Q1 2026.

• In Q1 2026, Common Equity fell 5.36% year-over-year to $523.1 million; the TTM figure through Mar 2026 stood at $523.1 million (down 5.36% YoY), while the FY2025 annual figure was $522.6 million, up 8.24% from the prior year.
• Common Equity was $523.1 million for Q1 2026 at Emergent BioSolutions, roughly flat from $522.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.6 billion in Q1 2022 to a low of $386.3 million in Q2 2024.
• Historically, Common Equity has averaged $833.1 million across 5 years, with a median of $649.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 59.66% in 2024, then surged 38.8% in 2025.
• A 5-year view of Common Equity shows it stood at $1.4 billion in 2022, then tumbled by 53.21% to $649.3 million in 2023, then slipped by 25.64% to $482.8 million in 2024, then rose by 8.24% to $522.6 million in 2025, then gained by 0.1% to $523.1 million in 2026.
• The last three Common Equity figures came in at $523.1 million (Q1 2026), $522.6 million (Q4 2025), and $582.5 million (Q3 2025), per Business Quant data.